TechCrunch·3 min read·medium
Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation
M
Marina Temkin
✦AI Summary
De-extinction startup Colossal Biosciences is reportedly seeking new funding at a valuation between $20 billion and $30 billion. The company is diversifying its revenue through conservation technology, spin-off startups, and potential future biodiversity credits.
When de-extinction startup Colossal Biosciences revealed last year that it was attempting to “resurrect” the dire wolf from genetic material found in fossils , we argued that, despite the controversy surrounding the project, the company was building valuable technologies that justify its $10.2 billion valuation.
technologybusinesssciencestartups
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in